Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 660 participants.
Also called NCT04429503
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 660 participants
- Sponsor
- Registry
-
NCT04429503 -
2019-003643-30
-
- Other papers using this trial's data
- Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Ninety-Six-Week Results from the Randomized Phase 2/3 PHOTON Trial
- Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial
- Intravitreal aflibercept 8 mg in patients from Japan with diabetic macular edema: 48-week subgroup analysis of the PHOTON trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Czechia, Germany, Hungary, Japan, Puerto Rico, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT04429503. Randomized; quadruple masking; primary purpose treatment. Start 2020-06-29 (actual); primary completion 2022-05-30 (actual). Results posted on 2023-11-21.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
- Acronym
- PHOTON
- Condition
- Diabetic Macular Edema
- Condition
- Type 1 Diabetes Mellitus
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- aflibercept
- Intervention (Drug)
- High-dose aflibercept
- Lead sponsor
- Regeneron Pharmaceuticals
- Collaborator
- Bayer
Record details
- Record id
cardio:ct-nct04429503- Content hash
c266333befb41c33c366448805c0a34ac2260fd799939fa3d67bf4347156ee68